Date: October 19, 2017

To: Local Health Departments
Infection Preventionists
Division of Quality Assurance
Wisconsin LTC D.O.N. Association
Wisconsin LTC Medical Directors Association
Wisconsin Healthcare Association
LeadingAge Wisconsin
Wisconsin Assisted Living Association

From: Thomas Haupt, M.S.
Wisconsin Division of Public Health

Reporting, prevention and control of acute respiratory illness outbreaks in long-term care facilities

PLEASE DISTRIBUTE WIDELY

This memo is intended as guidance to medical and administrative staff of long-term care facilities (LTCF) in Wisconsin. Guidance marked “required” is mandatory per Wisconsin Statute 252 or Wisconsin Administrative Code DHS 145.

It is left to the discretion of facility staff whether to use the remainder of this guidance wholly or in part, or to use recommendations from another source to prevent and control respiratory illness in their facility.

1.0 REPORTING

1.1 Reporting single cases
LTCF are required by State Statute 252 to report single cases of notifiable diseases to their local health department. Category I diseases require immediate notification by telephone; Category II diseases are required to be reported within 72 hours upon recognition of a case or suspected case either by entering the data into the Wisconsin Electronic Disease Surveillance System (WEDSS) or through notification of their local public health agency. A complete list of notifiable diseases and conditions can be found in Wisconsin Administrative Code DHS 145 Appendix A or at http://dhs.wisconsin.gov/communicable/diseasereporting/index.htm

1.2 Reporting outbreaks
An outbreak of any communicable disease within a LTCF is required, by State Statute .252, to be reported immediately by telephone to the local health department.
2.0 DEFINITION OF TERMS USED

2.1 A LTCF is defined as any Skilled Nursing Facility, Assisted Living Facility, Community-Based Residential Facility or Residential Care Apartment Complex.

2.2 Acute respiratory illness (ARI) is defined as illness characterized by any two (2) of the following:
- Fever*
- Cough (new or worsening, productive or nonproductive)
- Rhinorrhea (runny nose) or nasal congestion
- Sore throat
- Myalgia (muscle aches) greater than the resident’s norm

2.2.1 *Fever may be difficult to determine among elderly residents. Therefore, the definition of fever used for ARI is defined as temperature two degrees (2°F) above the established baseline for that resident.

2.3 Pneumonia is defined as radiographic evidence of new or increased pulmonary infiltrates, usually accompanied by fever. It is strongly recommended that all clinically-diagnosed pneumonia be followed with radiographic testing.

2.4 A respiratory disease outbreak in a LTCF is defined by DPH as three or more residents and/or staff from the same unit with illness onsets within 72 hours of each other and who have:
- Pneumonia, or
- ARI, or
- Laboratory-confirmed viral or bacterial infection (including influenza).

3.0 PREVENTION AND CONTROL OF RESPIRATORY OUTBREAKS IN LTCF

3.1 Influenza Vaccine
Influenza is the only respiratory virus for which there is a vaccine. The Centers for Disease Control and Prevention (CDC) has projected that a plentiful supply of influenza vaccine will be available in the United States during the 2016-17 influenza season. No delays in delivery have been identified or are currently anticipated. CDC and the Wisconsin Division of Public Health (DPH) recommend that all residents and employees of LTCF receive annual influenza vaccination as soon as influenza vaccine becomes available. Please note, intranasal vaccine is not available for the 2016-17 influenza season.

3.2 Laboratory Testing
When an outbreak of acute respiratory illness is suspected, consider collecting nasopharyngeal swabs (preferred) or oropharyngeal swabs from up to three ill residents or staff and, with DPH approval, send specimens to the Wisconsin State Laboratory of Hygiene (WSLH) for influenza and respiratory pathogens panel (RPP) testing. Testing will be done free of charge.

3.2.1 Specimens should be collected within five days after the onset of illness and placed in viral transport media to assure optimal test results.

3.2.2 Facilities may choose to have clinical specimens tested at a laboratory other than the WSLH; however, fee-exempt testing cannot be offered for tests performed at these laboratories.

3.2.3 Due to possible false positive results when using rapid influenza tests, especially when testing occurs during periods of low influenza activity, confirmatory testing of positive rapid test results using RT-PCR or viral culture should be performed.

3.2.4 With DPH approval, the specimens may also be tested for other respiratory viruses.

3.2.5 If test results confirm influenza within a facility, no further testing will be performed unless the resident has an atypical presentation of illness or is not responding to treatment.

3.2.6 Test results will be phoned to DPH and to the specimen submitter.

3.2.7 A negative test result does not rule out viral infection or the existence of an outbreak.
3.3 Antiviral Treatment and Prophylaxis during Influenza Outbreaks

3.3.1 Ideally, within 48 hours of the onset of illness, treat residents with confirmed or suspect cases of influenza with oseltamivir (Tamiflu®) or zanamivir (Relenza®), to reduce the severity and shorten the duration of illness.

3.3.2 At the discretion of a clinician, treatment with oseltamivir (Tamiflu®) or zanamivir (Relenza®) can be initiated more than 48 hours after the onset of illness.

3.3.3 Influenza antiviral prophylaxis may prevent further spread of infection during outbreaks of influenza in a LTCF.

3.3.4 When cases of influenza have been confirmed in a facility, antiviral prophylaxis should be offered to:

- All residents regardless of vaccination status,
- All unvaccinated employees, and
- Those employees vaccinated less than two weeks before the cases were identified.

3.3.5 In seasons when the influenza vaccine strain does not adequately match the circulating strain of influenza, all residents and staff, regardless of vaccination status, should be offered antiviral prophylaxis.

3.3.6 Both oseltamivir (Tamiflu®) and zanamivir (Relenza®) can be used for antiviral prophylaxis to prevent influenza A and B infection.

3.3.7 Once initiated, antiviral prophylaxis should continue for a minimum of two weeks, and continue up to seven days after the last known case was identified.

3.3.8 For a resident with a known creatinine clearance of 10-30 mL per minute, a reduction of the treatment dosage of oseltamivir and in the prophylaxis dosage is recommended. Refer to CDC recommendations in 3.3.10.

NOTE: It is not necessary for residents to have their creatinine clearance checked prior to receiving oseltamivir treatment or prophylaxis.

3.3.9 Because of identified resistance, adamantanes should not be used to treat or prevent cases of influenza A. Both pd2009/H1N1 and seasonal H3N2 viruses are resistant to adamantanes (amantadine, rimantadine, Symadine®, Symmetrel®, Flumadine®). Adamantanes are not effective against influenza B.

3.3.10 CDC influenza antiviral recommendations can be found at: http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm

4.0 Infection Control

Caregivers and visitors should adhere to the appropriate precautions when in the presence of a resident with suspected or confirmed respiratory illness. Until the cause(s) of an ARI outbreak is determined, both droplet and contact precautions should be initiated in addition to standard precautions.

4.1 Droplet Precautions are intended to prevent transmission of pathogens spread through close respiratory or mucous membrane contact with respiratory secretions. In contrast to contact transmission, respiratory droplets carry and transmit infectious pathogens when they travel directly from the respiratory tract of the infectious individual to susceptible mucosal surfaces of the recipient, generally over short distances.

4.1.1 Health care personnel should wear a mask (a respirator is not necessary) for close contact with an ill resident. The mask is generally donned immediately prior to room entry.

4.1.2 Residents on droplet precautions who must be transported outside of their room should wear a mask if tolerated and practice respiratory hygiene/cough etiquette.

4.2 Contact Precautions apply when the presence of discharges from the body suggest an increased potential for extensive environmental contamination and risk of transmission.

4.2.1 Health care staff should wear a gown and gloves for all interactions that may involve direct contact with the resident or potentially contaminated areas in the environment.
4.2.2 Donning PPE immediately prior to room entry and discarding before exiting the room to contain pathogens implicated in direct transmission or indirect transmission through environmental contamination.

4.3 CDC Recommended Precautions for Common Respiratory Viruses

<table>
<thead>
<tr>
<th></th>
<th>Droplet Precautions</th>
<th>Contact Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>RSV</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Parainfluenza</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Rhino/enterovirus</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Coronavirus</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Human metapneumovirus</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Adenovirus</td>
<td>√</td>
<td>√</td>
</tr>
</tbody>
</table>

4.3.1 When test results fail to identify an etiologic agent, ill residents should continue to be placed on contact and droplet precautions.

4.4 Duration of Contact and Droplet Precautions

4.4.1 When a resident has confirmed or suspected influenza, the resident should remain on droplet precautions for seven days after onset of illness or until 24 hours after the resolution of fever and respiratory symptoms (see Section 4.4.3 below), whichever is longer.

4.4.2 For other respiratory illnesses, the resident should remain on appropriate precautions for the duration of illness, defined as 24 hours after resolution of fever without the use of fever-reducing medications and without respiratory symptoms (see Section 4.4.3 below).

4.4.3 Criteria for determining ARI among staff or residents should focus on whether cough is a new or worsening symptom. For discontinuation of droplet or contact precautions, exclude cough as a criterion unless the cough produces purulent sputum. In many cases, a non-infectious post viral cough may continue for several weeks following resolution of other respiratory symptoms.

4.5 Resident Room Assignments during an Outbreak

4.5.1 Ideally, if possible, an ill resident should be in a private room.

4.5.2 Decisions by medical and administrative staff regarding resident placement should be made on a case-by-case basis. In determining resident placement, consider:

- Balancing the risk of infection to other residents in the room.
- The presence of risk factors that increase the likelihood of transmission within the facility.
- The potential adverse psychological impact on the infected resident.

4.5.3 When a single-resident room is not available, ill residents can be placed in a multi-bed room following consultation with infection control personnel to assess risks associated with resident placement options (e.g., cohorting, keeping the resident with an existing roommate).

4.5.4 Spatial separation of three feet or more and drawing the curtain between resident beds is especially important for residents in multi-bed rooms.

4.5.5 The LTCF may consider allowing a resident with a cough to leave their room while wearing a surgical mask, if the resident’s understanding and compliance with mask use will minimize the risk of infection to other residents.

4.5.6 Non-ill residents should not be confined or restricted to their rooms during an outbreak.
4.6 Visitors
4.6.1 Upon recognition of a confirmed or suspected outbreak of acute respiratory illness, the facility may consider posting a sign on each entrance informing visitors of the outbreak.
4.6.2 Ill visitors can be restricted but not denied from entering the facility. It is recommended by CDC and DPH that if an ill visitor must enter the facility (e.g., end-of-life situations), the facility should provide the visitor with a surgical mask.
4.6.3 LTCF should not restrict asymptomatic visitors from entering their facility.
4.6.4 Visitors should comply with the facility’s implemented droplet and contact precautions.

4.7 Restriction of New Admissions to an LTCF
4.7.1 Upon recognition of a confirmed or suspected outbreak of respiratory illness, the facility may consider restricting new admissions to the facility.
4.7.2 If the outbreak is confined to a specific unit, wing, or floor, the facility may consider allowing new admissions to other units, wings, or floors not affected by the outbreak.
4.7.3 Restriction of new admissions to the facility or the affected unit, wing, or floor may be considered until one week after the illness onset of the last confirmed or suspected case.

4.8 Readmission of Current Residents
4.8.1 The facility should consider the readmission of ill residents (example, those returning from a hospital stay), provided that upon return to the facility, the appropriate infection control measures are implemented to protect the health of other residents. See section 4.5 above.
4.8.2 Laboratory testing of residents for ARI (including influenza) prior to readmission is not recommended and should not be used as criterion for readmission to the facility.

4.9 Exclusion of Staff with ARI
4.9.1 Staff should be excluded from work until at least 24 hours after they no longer have a fever (without the use of fever-reducing medicines such as acetaminophen or ibuprofen).
4.9.2 If symptoms such as cough and sneezing are still present, staff should wear a surgical mask during resident care activities.

4.10 Participation in Activities, Therapy, and Communal Dining During an Outbreak
4.10.1 An outbreak of ARI does not require the cancellation of facility-wide resident activities, therapy, or communal dining.
4.10.2 Residents with active ARI should not participate in facility-wide resident activities, therapy, or communal dining.

References
Infection Control Guidelines (CDC)
http://www.cdc.gov/flu/professionals/infectioncontrol/index.htm

DPH/ Bureau of Communicable Diseases (BCD) Websites
http://www.dhs.wisconsin.gov/immunization/index.htm (immunization)
https://www.dhs.wisconsin.gov/influenza/reporting.htm
https://www.dhs.wisconsin.gov/influenza/index.htm (surveillance)

Direct questions, comments, or concerns to:
608-266-5326 Thomas Haupt, Influenza Surveillance Coordinator
608-267-9003 Bureau of Communicable Diseases
### Patient Information
<table>
<thead>
<tr>
<th>Name (Last, First):</th>
<th>(Your Institution’s Agency Number If Known)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address:</td>
<td>(Your Institution’s Name)</td>
</tr>
<tr>
<td>City:</td>
<td>State: Zip:</td>
</tr>
<tr>
<td>Date of Birth:</td>
<td>Gender: M F</td>
</tr>
<tr>
<td>Occupation:</td>
<td>(Telephone Number)</td>
</tr>
<tr>
<td>Your Patient ID Number (optional):</td>
<td></td>
</tr>
<tr>
<td>Your Specimen ID Number (optional):</td>
<td>WSLH Use Only Study: VI SURV-NHANCED WSLH Use Only: Bill To: (WSLH Account # 74201)</td>
</tr>
</tbody>
</table>

### Reason for submission:
- [ ] Outbreak Investigation (name & location)______________________________
- [ ] Swine Contact
- [ ] Avian Influenza Suspect
- [ ] MERS-Coronavirus Suspect
- [ ] Other______________________________

### Date Collected:
- [ ] Combined Throat/Nasopharynx Swab
- [ ] Nasopharynx Swab (in VTM)
- [ ] Throat Swab (VTM)

### Date of Onset:

<table>
<thead>
<tr>
<th>General</th>
<th>Symptoms</th>
<th>Respiratory Symptoms</th>
<th>Digestive Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anorexia</td>
<td></td>
<td>Conjunctivitis</td>
<td>Diarrhea</td>
</tr>
<tr>
<td>Arthralgia</td>
<td></td>
<td>Ear Pain</td>
<td>Nausea / Vomiting</td>
</tr>
<tr>
<td>Fever</td>
<td></td>
<td>Nasal Congestion</td>
<td>CNS</td>
</tr>
<tr>
<td>Headache</td>
<td></td>
<td>Nasal Discharge</td>
<td>Encephalopathy</td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td></td>
<td>Pharyngitis</td>
<td>Delirium</td>
</tr>
<tr>
<td>Malaise</td>
<td></td>
<td>Hoarseness</td>
<td>Meningismus</td>
</tr>
<tr>
<td>Myalgia</td>
<td></td>
<td>Cough (circle one)</td>
<td>productive / nonproductive / barking</td>
</tr>
<tr>
<td>Photophobia</td>
<td></td>
<td>Crackles</td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td></td>
<td>Dyspnea</td>
<td></td>
</tr>
<tr>
<td>Mouth Lesions</td>
<td></td>
<td>Wheeze</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pneumonia</td>
</tr>
</tbody>
</table>

### Vaccination History (Influenza): Was patient vaccinated?
- [ ] Yes
- [ ] No
- [ ] Unknown

If Yes, Date Vaccinated:

### Travel History (Places and dates):

Was patient hospitalized?
- [ ] Yes
- [ ] No
- [ ] Unknown

If Yes, where: ____________________________________________
Monitor all residents and staff for signs and symptoms consistent with acute respiratory illness (ARI) Section 2.2

If an outbreak of ARI is identified, notify the local health department, the facility medical director, and administration: enhance surveillance for ARI among residents and staff, Section 2.3, and institute appropriate infection control precautions, Section 4.

Test residents/staff who present with ARI by submitting respiratory specimens to the WSLH or a laboratory equipped to test for multiple respiratory viruses. Section 3.2

One or more test results are positive for influenza. Section 3.2

Within 48 hours of the onset of illness, treat confirmed and suspect cases among residents and staff with oseltamivir (Tamiflu®) or zanamivir (Relenza®) to reduce the severity and shorten the duration of the illness. Section 3.3

Notify facility medical staff or resident’s personal clinician. Consider providing antiviral chemoprophylaxis to:
- ALL unvaccinated employees and those employees vaccinated less than two weeks before the cases were identified, and
- ALL residents regardless of vaccination status, unless exposure is limited to a specific unit, wing or floor. Section 3.3

One or more test results are positive for a pathogen other than influenza or all test results are negative. Section 3.2

Facility medical staff may consider restricting new admissions to the facility or to the area where the confirmed resident(s) reside until one week after the illness onset of the last confirmed or suspect case. Section 4.7
Shipment of Surveillance Specimens via Gold Cross Courier

Specimen Packaging (WSLH Kit # 18 or equivalent):
- Triple package as "Biological substance, Category B / UN 3373"
- Securely tape the cap of the specimen container, wrap specimen with absorbent material; place the specimen vial into a biohazard bag; place the completed requisition form into the outer pocket of the bag.
- Place the bagged specimen and form in the styrofoam mailer with a frozen kool-pak and cushioning.
- Replace lid on the styrofoam/cardboard box; close and securely tape the cardboard box shut.
- Attach the WSLH address label to the package:
  Wisconsin State Lab of Hygiene
  Communicable Disease Division
  PO Box 7904
  2601 Agriculture Drive
  Madison, WI 53718
- Attach the ‘Biological substance, Category B / UN 3373’ label to the package.
- Attach your return address label
- Include the name and telephone number of the person who knows the content of the package (requirement) with the return address

Specimen Collection & Shipping Supplies:
- Specimen collection and shipping supplies are available at no cost to surveillance sites. Please contact the WSLH Clinical Orders dept. at 800-862-1088 to order supplies.

Shipping Arrangements:
- The WSLH has a contract with GOLD CROSS for shipment of specimens to the WSLH, with charges billed to the WSLH. You are not required to ship via GOLD CROSS unless you wish to have the transport charges billed to the WSLH.
- Specimens will be picked up during regular working hours, but you must confirm the time with the GOLD CROSS scheduler.
- Specimens will be delivered to the WSLH the following day. If you must ship on Fridays or on the day before a holiday, please include an extra coolant.
- All package preparation should be completed before the courier arrives.
- Contact GOLD CROSS directly to arrange for a pick-up
  CALL: 800-990-9668
  Website: http://goldcrosscourier.com/

NOTE: THIS ACCOUNT IS FOR SURVEILLANCE SPECIMENS OR OTHERS REQUESTED BY WSLH! Funding is NOT available for transport of other samples.